Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging ...
Bayer's darolutamide plus ADT reduced radiological progression or death risk by 46% in mHSPC patients, with positive data both with and without docetaxel. The results were presented at the 2024 ESMO Congress and published in The Journal of Clinical Oncology. Bayer plans to submit the ARANOTE trial data to health authorities for expanded darolutamide use in mHSPC.
Reference News
Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging ...
Bayer's darolutamide plus ADT reduced radiological progression or death risk by 46% in mHSPC patients, with positive data both with and without docetaxel. The results were presented at the 2024 ESMO Congress and published in The Journal of Clinical Oncology. Bayer plans to submit the ARANOTE trial data to health authorities for expanded darolutamide use in mHSPC.